Our goal is to enable the next generation of personalized treatment strategies, beginning with pancreatic cancer and extending far beyond. Our first planned test to reach the market is PancEpistemeDx™. Episteme’s PancEpistemeDx™ uses Accessible Chromatin Region (ACR) signatures to identify non-responders to chemotherapy in pancreatic cancer with 99% accuracy.
Science and Technology
The Biological Insight
Cancer treatment response is more than genetics.
DNA Sequence
What mutations are present?
Genetic mutations are important, but they do not explain how cancer cells behave or why they respond, or don’t respond, to treatment.
Chromatin Accessibility
Which parts of the genome are active?
Chromatin accessibility reflects the regulatory state of the genome, shaping gene activity and driving cancer cell behavior and treatment response.
01
ACR Signatures
Episteme’s platform analyzes Accessible Chromatin Region (ACR) signatures, which capture the combined effect of methylation, histone marks, chromatin remodeling, and actionable mutations.
PancEpistemeDx™ uses ACR signatures to identify non-responders to chemotherapy in pancreatic cancer with high accuracy. (Dhara et al., Nature Communications 2021)
02
PancEpistemeDx™
Intended Use / Development Objective.
To predict whether or not chemotherapy will work in patients with pancreatic cancer.
How It Works.
Tumor sample → ACR analysis → Predict treatment response (Responder vs. Non-responder)
Development Status
PancEpistemeDx™ is currently in development and is not yet commercially available. Commercial launch is planned for 2027 following regulatory approvals.
03
Clinical Evidence
Our findings are published in peer-reviewed journals and presented at major scientific meetings.
- Dhara et al., Nature Communications 2021
- Data presented at the AACR Annual Meeting 2026
- Additional validation studies are ongoing
04
tCAM-seq™: Our Next Breakthrough Platform
tCAM-seq™ (Targeted Chromatin Accessibility and Mutation – Sequencing) is an ultradeep sequencing technology that enables simultaneous detection of chromatin accessibility signatures and actionable mutations from a single specimen. (Data disclosed at the AACR Annual Meeting 2026).
05
Platform Potential
Our technology is broadly applicable across multiple cancer types and therapeutic contexts, and not limited to a single indication.
06
Partnering With Biopharma
Biomarker Discovery
Identify chromatin signatures associated with drug response.
Patient Stratification
Select patients most likely to respond to investigational therapies.
Clinical Trial Development
Improve trial design and enrich for responsive populations.
Companion Diagnostics (CDx)
Develop diagnostic solutions for targeted and epigenetic therapies.
07
Epigenetic modulators and CDx opportunity: Epigenetic modulators are gaining significant momentum and are rapidly progressing through clinical trials. Our technology has the potential to identify patients most likely to respond to these novel therapies, thereby increasing the likelihood of success in clinical trials involving epigenetic drugs. As a result, our platform is ideally positioned to partner with biopharmaceutical companies in the development of companion diagnostics (CDx) for epigenetic treatments.